Award
NIH Reporter #3R34AI198088-01S1
Aggressive antipyretics for neuroprotection and mortality reduction in CNS malaria: A Randomized-Controlled Trial
Recipient
University of Rochester
Award Amount
$8,952.00
Ceiling
$8,952.00
Awarded
September 08, 2026
Identifier
3R34AI198088-01S1
A NIH-funded phase III randomized controlled trial led by University of Rochester to assess aggressive antipyretic therapy for neuroprotection and mortality reduction in pediatric CNS malaria.
Description
This project involves a phase III randomized controlled trial to evaluate the efficacy of adjunctive aggressive antipyretic therapy in pediatric CNS malaria. The project is funded by NIH and involves international collaboration in Malawi, Zambia, and DRC. The primary outcome measures include mortality, neurodisability, and epilepsy within 3 years post-infection.